NBIX

Q: What is the price of Neurocrine (NBIX) today?

The current price of Neurocrine (NBIX) is $ 130.81. The stock began the year trading around $ 141.83 and is currently priced at $ 130.81. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Neurocrine (NBIX) pay dividends?

Neurocrine (NBIX) did not pay dividends over the past year.

Q: Is Neurocrine (NBIX) a good investment?

Neurocrine (NBIX) is currently trading at $ 130.81 with a P/E ratio of 27.51. This represents a 4,840% premium compared to its historical average P/E. Over the past year, the stock paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

Neurocrine Biosciences Inc.

Price

$ 130.81

return (12m)

p/e

27.51

p/bv

4.05

DIVIDEND YIELD

0.00%

NBIX price

Neurocrine

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment NBIX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals NBIX

review the fundamentals of Neurocrine shares

P/E

27.51

Sector: -4.09 Industry: -4.09

P/Receita (PSR)

4.60

Sector: -3.87 Industry: -3.87

P/BV

4.05

Sector: 1.89 Industry: 1.89

Dividend Yield (DY)

0.00%

Sector: - Industry: -

Payout

0.00%

Sector: - Industry: -

Net Profit Margins

16.73%

Sector: -39.07% Industry: -39.07%

Gross Margin

98.18%

Sector: 37.83% Industry: 37.83%

Margem Operacional

22.25%

Sector: -39.17% Industry: -39.17%

Margem EBIT

28.29%

Sector: - Industry: -

Margem EBITDA

29.22%

Sector: - Industry: -

EV/EBITDA

49.65

Sector: - Industry: -

EV/EBIT

51.28

Sector: - Industry: -

EV/EBITDA

19.75

Sector: -3.91 Industry: -3.91

EV/EBIT

20.69

Sector: -4.18 Industry: -4.18

P/Ativo

2.84

Sector: 1.39 Industry: 1.39

P/Cap Giro

7.40

Sector: - Industry: -

P/Ativo Circ Líq

11.51

Sector: - Industry: -

BVPS

32.53

Sector: 1.88 Industry: 1.88

EPS

4.79

Sector: -2.04 Industry: -2.04

Giro de Ativos

0.17

Sector: - Industry: -

ROE

14.71%

Sector: -61.00% Industry: -61.00%

ROIC

20.39%

Sector: -2,142.55% Industry: -2,142.55%

ROA

10.33%

Sector: -61.28% Industry: -61.28%

Dívida Líquida / Patrimônio

-0.46

Sector: - Industry: -

Dívida Líquida / EBITDA

-6.29

Sector: - Industry: -

Dívida Líquida / EBIT

-6.50

Sector: - Industry: -

Dívida Bruta / Patrimônio

0.00

Sector: - Industry: -

Patrimônio / Ativos

0.70

Sector: 0.42 Industry: 0.42

Passivos / Ativos

0.30

Sector: 0.38 Industry: 0.38

Liquidez Corrente

3.39

Sector: - Industry: -

CAGR Receitas 5 Anos

20.34%

Sector: - Industry: -

CAGR Lucros 5 Anos

39.81%

Sector: - Industry: -

FAIR VALUE OF Neurocrine ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$130.81

Fair Value

$59.21

Upside/Downside Return potential.

-54.74%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals NBIX

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
NBIX	27.51	4.05	14.71%	0.00%	$13.17 B	16.73%
AZN	27.54	6.04	21.93%	1.73%	$286.16 B	17.19%
JNJ	26.01	6.74	25.92%	2.29%	$547.30 B	21.83%
ABEO	4.20	1.88	44.71%	0.00%	$298.65 M	100.00%
PFE	19.27	1.61	8.35%	6.53%	$149.71 B	12.42%
ABBV	100.54	0.00	0.00%	3.22%	$365.48 B	5.79%
ACAD	9.54	3.04	31.86%	0.00%	$3.73 B	36.49%
ADMA	17.04	5.25	30.78%	0.00%	$2.50 B	28.80%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NBIX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Neurocrine

Neurocrine Biosciences Inc.

Average Investor10 user rating

4.0 (0 people)

States of America

34 years

Founded: 1992

1996

Time since IPO - 30 years

845

Employees

Neurocrine Biosciences Inc. (States of America) is listed on the Nasdaq and has a market capitalization of $13.17 billion, with shareholders equity totaling $3.25 billion.

The company employs approximately 845 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, Neurocrine Biosciences Inc. reported $2.86 billion in revenue, generating net income of $478.60 million.

Key financial metrics include a P/E ratio of 27.51, a price-to-book (P/B) ratio of 4.05, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NBIX.

Market cap

$13.17 billion

Net worth

$3.25 billion

$ 3,253,100,000.00

Assets

$4.63 billion

$ 4,631,500,000.00

Total Shares Outstanding

100.00 million

100,000,000

Average Daily Trading Volume

$1.08 million

$ 1,079,975.30

Sector

Healthcare

Industry

Biotecnologia

NBIX

NBIX revenue and profits

Financial Results NBIX

DRAG THE FRAME TO SEE MORE DATA

NBIX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 21,75% (12M)

P/E

23.07

0.39%

ROE

-4,383.84%

P/BV

-1,011.36

CAH - Cardinal Health

$214.95 41,04% (12M)

P/E

29.51

1.05%

ROE

-58.20%

P/BV

-17.17

JNJ - Johnson & Johnson

$240.16 60,65% (12M)

P/E

26.01

2.29%

ROE

25.92%

P/BV

6.74

PFE - Pfizer

$27.11 25,77% (12M)

P/E

19.27

6.53%

ROE

8.35%

P/BV

1.61

MRK - Merck & Co.

$119.96 60,16% (12M)

P/E

31.01

2.96%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$204.64 42,91% (12M)

P/E

27.54

1.73%

ROE

21.93%

P/BV

6.04

ABBV - AbbVie

$210.26 15,72% (12M)

P/E

100.54

3.22%

ROE

0.00%

P/BV

0.00

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$862.96 21,75% (12 M)

P/L

23.07

0.39%

ROE

-4,383.84%

P/VP

-1,011.36

CAH - Cardinal Health

$214.95 41,04% (12 M)

P/L

29.51

1.05%

ROE

-58.20%

P/VP

-17.17

JNJ - Johnson & Johnson

$240.16 60,65% (12 M)

P/L

26.01

2.29%

ROE

25.92%

P/VP

6.74

PFE - Pfizer

$27.11 25,77% (12 M)

P/L

19.27

6.53%

ROE

8.35%

P/VP

1.61

MRK - Merck & Co.

$119.96 60,16% (12 M)

P/L

31.01

2.96%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$204.64 42,91% (12 M)

P/L

27.54

1.73%

ROE

21.93%

P/VP

6.04

ABBV - AbbVie

$210.26 15,72% (12 M)

P/L

100.54

3.22%

ROE

0.00%

P/VP

0.00

Frequently Asked Questions

What is the price of Neurocrine (NBIX) today?

The current price of Neurocrine (NBIX) is $ 130.81. The stock began the year trading around $ 141.83 and is currently priced at $ 130.81. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Neurocrine (NBIX) pay dividends?

Neurocrine (NBIX) did not pay dividends over the past year.

Is Neurocrine (NBIX) a good investment?

Neurocrine (NBIX) is currently trading at $ 130.81 with a P/E ratio of 27.51. This represents a 4,840% premium compared to its historical average P/E. Over the past year, the stock paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Neurocrine (NBIX) stock?

You can buy Neurocrine (NBIX) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol NBIX and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Neurocrine (NBIX) yield today?

Over the past month, Neurocrine (NBIX) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Neurocrine (NBIX) today at the current price of $ 130.81 your total investment would be $ 13,081.00.

Based on historical performance, the investment would have grown to approximately:

$ 13,081.00 after 1 year
$ 13,081.00 after 5 years
$ 13,081.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NBIX

Neurocrine Biosciences Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NBIX

review the fundamentals of Neurocrine shares

P/E

P/Receita (PSR)

P/BV

Dividend Yield (DY)

Payout

Net Profit Margins

Gross Margin

Margem Operacional

Margem EBIT

Margem EBITDA

EV/EBITDA

EV/EBIT

EV/EBITDA

EV/EBIT

P/Ativo

P/Cap Giro

P/Ativo Circ Líq

BVPS

EPS

Giro de Ativos

ROE

ROIC

ROA

Dívida Líquida / Patrimônio

Dívida Líquida / EBITDA

Dívida Líquida / EBIT

Dívida Bruta / Patrimônio

Patrimônio / Ativos

Passivos / Ativos

Liquidez Corrente

CAGR Receitas 5 Anos

CAGR Lucros 5 Anos

Graham's Fair Value

current DY: 0.00%

5-year average DY: 0.00%

Neurocrine Biosciences Inc.

States of America

34 years

1996

845

PROFIT X PRICE NBIX

Financial Results NBIX

NBIX cash flow

Asset, Revenue and Profit Growth - NBIX

NBIX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

Frequently Asked Questions